No Cover Image

Journal article 724 views 147 downloads

Adding Celecoxib With or Without Zoledronic Acid for Hormone-Naïve Prostate Cancer: Long-Term Survival Results From an Adaptive, Multiarm, Multistage, Platform, Randomized Controlled Trial

Malcolm D. Mason, Noel W. Clarke, Nicholas D. James, David P. Dearnaley, Melissa R. Spears, Alastair W.S. Ritchie, Gerhardt Attard, William Cross, Rob J. Jones, Christopher C. Parker, J. Martin Russell, George N. Thalmann, Francesca Schiavone, Estelle Cassoly, David Matheson, Robin Millman, Cyrill A. Rentsch, Jim Barber, Clare Gilson, Azman Ibrahim, John Logue, Anna Lydon, Ashok D. Nikapota, Joe M. O’Sullivan, Emilio Porfiri, Andrew Protheroe, Narayanan Nair Srihari, David Tsang, John Wagstaff, Jan Wallace, Catherine Walmsley, Mahesh K.B. Parmar, Matthew R. Sydes

Journal of Clinical Oncology, Volume: 35, Issue: 14, Pages: 1530 - 1541

Swansea University Author: John Wagstaff

Check full text

DOI (Published version): 10.1200/JCO.2016.69.0677

Abstract

In this multiform, multistage trial 1245 men with high risk locally advanced or metastatic prostate cancer were treated with standard of care hormone therapy (SOCHT) and randomised (2:1:1) to receive SOCHT alone, SOCHT plus celecoxib (cel) or SOCHT plus cele plus zoledronic acid (ZA). Prostate (+/-...

Full description

Published in: Journal of Clinical Oncology
ISSN: 0732-183X 1527-7755
Published: 2017
Online Access: Check full text

URI: https://cronfa.swan.ac.uk/Record/cronfa33243
first_indexed 2017-05-06T13:07:45Z
last_indexed 2018-02-09T05:22:02Z
id cronfa33243
recordtype SURis
fullrecord <?xml version="1.0"?><rfc1807><datestamp>2017-09-15T14:38:47.6705760</datestamp><bib-version>v2</bib-version><id>33243</id><entry>2017-05-06</entry><title>Adding Celecoxib With or Without Zoledronic Acid for Hormone-Na&#xEF;ve Prostate Cancer: Long-Term Survival Results From an Adaptive, Multiarm, Multistage, Platform, Randomized Controlled Trial</title><swanseaauthors><author><sid>fdab5e9e2fe06c93d3ffa19c816bdcf6</sid><firstname>John</firstname><surname>Wagstaff</surname><name>John Wagstaff</name><active>true</active><ethesisStudent>false</ethesisStudent></author></swanseaauthors><date>2017-05-06</date><deptcode>MEDS</deptcode><abstract>In this multiform, multistage trial 1245 men with high risk locally advanced or metastatic prostate cancer were treated with standard of care hormone therapy (SOCHT) and randomised (2:1:1) to receive SOCHT alone, SOCHT plus celecoxib (cel) or SOCHT plus cele plus zoledronic acid (ZA). Prostate (+/- pelvic) radiotherapy was encouraged for men with localised disease. In the SOCHT arm median survival was 66 months. The hazard ratio for death in the SOCHT + cel arm was 0.98 (95% CI 0.80 to 1.20, median survival 70 months, p=0.847). The hazard ratio for death in the SOCHT + cel + ZA was 0.86 (95% CI 0.70 to 1.05, median survival 76 months, p=0.13). these data show no overall evidence of improved survival with cel.</abstract><type>Journal Article</type><journal>Journal of Clinical Oncology</journal><volume>35</volume><journalNumber>14</journalNumber><paginationStart>1530</paginationStart><paginationEnd>1541</paginationEnd><publisher/><issnPrint>0732-183X</issnPrint><issnElectronic>1527-7755</issnElectronic><keywords/><publishedDay>10</publishedDay><publishedMonth>5</publishedMonth><publishedYear>2017</publishedYear><publishedDate>2017-05-10</publishedDate><doi>10.1200/JCO.2016.69.0677</doi><url/><notes/><college>COLLEGE NANME</college><department>Medical School</department><CollegeCode>COLLEGE CODE</CollegeCode><DepartmentCode>MEDS</DepartmentCode><institution>Swansea University</institution><apcterm/><lastEdited>2017-09-15T14:38:47.6705760</lastEdited><Created>2017-05-06T10:49:55.9543495</Created><path><level id="1">Faculty of Medicine, Health and Life Sciences</level><level id="2">Swansea University Medical School - Medicine</level></path><authors><author><firstname>Malcolm D.</firstname><surname>Mason</surname><order>1</order></author><author><firstname>Noel W.</firstname><surname>Clarke</surname><order>2</order></author><author><firstname>Nicholas D.</firstname><surname>James</surname><order>3</order></author><author><firstname>David P.</firstname><surname>Dearnaley</surname><order>4</order></author><author><firstname>Melissa R.</firstname><surname>Spears</surname><order>5</order></author><author><firstname>Alastair W.S.</firstname><surname>Ritchie</surname><order>6</order></author><author><firstname>Gerhardt</firstname><surname>Attard</surname><order>7</order></author><author><firstname>William</firstname><surname>Cross</surname><order>8</order></author><author><firstname>Rob J.</firstname><surname>Jones</surname><order>9</order></author><author><firstname>Christopher C.</firstname><surname>Parker</surname><order>10</order></author><author><firstname>J. Martin</firstname><surname>Russell</surname><order>11</order></author><author><firstname>George N.</firstname><surname>Thalmann</surname><order>12</order></author><author><firstname>Francesca</firstname><surname>Schiavone</surname><order>13</order></author><author><firstname>Estelle</firstname><surname>Cassoly</surname><order>14</order></author><author><firstname>David</firstname><surname>Matheson</surname><order>15</order></author><author><firstname>Robin</firstname><surname>Millman</surname><order>16</order></author><author><firstname>Cyrill A.</firstname><surname>Rentsch</surname><order>17</order></author><author><firstname>Jim</firstname><surname>Barber</surname><order>18</order></author><author><firstname>Clare</firstname><surname>Gilson</surname><order>19</order></author><author><firstname>Azman</firstname><surname>Ibrahim</surname><order>20</order></author><author><firstname>John</firstname><surname>Logue</surname><order>21</order></author><author><firstname>Anna</firstname><surname>Lydon</surname><order>22</order></author><author><firstname>Ashok D.</firstname><surname>Nikapota</surname><order>23</order></author><author><firstname>Joe M.</firstname><surname>O&#x2019;Sullivan</surname><order>24</order></author><author><firstname>Emilio</firstname><surname>Porfiri</surname><order>25</order></author><author><firstname>Andrew</firstname><surname>Protheroe</surname><order>26</order></author><author><firstname>Narayanan Nair</firstname><surname>Srihari</surname><order>27</order></author><author><firstname>David</firstname><surname>Tsang</surname><order>28</order></author><author><firstname>John</firstname><surname>Wagstaff</surname><order>29</order></author><author><firstname>Jan</firstname><surname>Wallace</surname><order>30</order></author><author><firstname>Catherine</firstname><surname>Walmsley</surname><order>31</order></author><author><firstname>Mahesh K.B.</firstname><surname>Parmar</surname><order>32</order></author><author><firstname>Matthew R.</firstname><surname>Sydes</surname><order>33</order></author></authors><documents><document><filename>0033243-06062017132946.pdf</filename><originalFilename>jco.2016.69.0677.pdf</originalFilename><uploaded>2017-06-06T13:29:46.1570000</uploaded><type>Output</type><contentLength>1110767</contentLength><contentType>application/pdf</contentType><version>Version of Record</version><cronfaStatus>true</cronfaStatus><embargoDate>2017-05-10T00:00:00.0000000</embargoDate><copyrightCorrect>true</copyrightCorrect><language>eng</language></document></documents><OutputDurs/></rfc1807>
spelling 2017-09-15T14:38:47.6705760 v2 33243 2017-05-06 Adding Celecoxib With or Without Zoledronic Acid for Hormone-Naïve Prostate Cancer: Long-Term Survival Results From an Adaptive, Multiarm, Multistage, Platform, Randomized Controlled Trial fdab5e9e2fe06c93d3ffa19c816bdcf6 John Wagstaff John Wagstaff true false 2017-05-06 MEDS In this multiform, multistage trial 1245 men with high risk locally advanced or metastatic prostate cancer were treated with standard of care hormone therapy (SOCHT) and randomised (2:1:1) to receive SOCHT alone, SOCHT plus celecoxib (cel) or SOCHT plus cele plus zoledronic acid (ZA). Prostate (+/- pelvic) radiotherapy was encouraged for men with localised disease. In the SOCHT arm median survival was 66 months. The hazard ratio for death in the SOCHT + cel arm was 0.98 (95% CI 0.80 to 1.20, median survival 70 months, p=0.847). The hazard ratio for death in the SOCHT + cel + ZA was 0.86 (95% CI 0.70 to 1.05, median survival 76 months, p=0.13). these data show no overall evidence of improved survival with cel. Journal Article Journal of Clinical Oncology 35 14 1530 1541 0732-183X 1527-7755 10 5 2017 2017-05-10 10.1200/JCO.2016.69.0677 COLLEGE NANME Medical School COLLEGE CODE MEDS Swansea University 2017-09-15T14:38:47.6705760 2017-05-06T10:49:55.9543495 Faculty of Medicine, Health and Life Sciences Swansea University Medical School - Medicine Malcolm D. Mason 1 Noel W. Clarke 2 Nicholas D. James 3 David P. Dearnaley 4 Melissa R. Spears 5 Alastair W.S. Ritchie 6 Gerhardt Attard 7 William Cross 8 Rob J. Jones 9 Christopher C. Parker 10 J. Martin Russell 11 George N. Thalmann 12 Francesca Schiavone 13 Estelle Cassoly 14 David Matheson 15 Robin Millman 16 Cyrill A. Rentsch 17 Jim Barber 18 Clare Gilson 19 Azman Ibrahim 20 John Logue 21 Anna Lydon 22 Ashok D. Nikapota 23 Joe M. O’Sullivan 24 Emilio Porfiri 25 Andrew Protheroe 26 Narayanan Nair Srihari 27 David Tsang 28 John Wagstaff 29 Jan Wallace 30 Catherine Walmsley 31 Mahesh K.B. Parmar 32 Matthew R. Sydes 33 0033243-06062017132946.pdf jco.2016.69.0677.pdf 2017-06-06T13:29:46.1570000 Output 1110767 application/pdf Version of Record true 2017-05-10T00:00:00.0000000 true eng
title Adding Celecoxib With or Without Zoledronic Acid for Hormone-Naïve Prostate Cancer: Long-Term Survival Results From an Adaptive, Multiarm, Multistage, Platform, Randomized Controlled Trial
spellingShingle Adding Celecoxib With or Without Zoledronic Acid for Hormone-Naïve Prostate Cancer: Long-Term Survival Results From an Adaptive, Multiarm, Multistage, Platform, Randomized Controlled Trial
John Wagstaff
title_short Adding Celecoxib With or Without Zoledronic Acid for Hormone-Naïve Prostate Cancer: Long-Term Survival Results From an Adaptive, Multiarm, Multistage, Platform, Randomized Controlled Trial
title_full Adding Celecoxib With or Without Zoledronic Acid for Hormone-Naïve Prostate Cancer: Long-Term Survival Results From an Adaptive, Multiarm, Multistage, Platform, Randomized Controlled Trial
title_fullStr Adding Celecoxib With or Without Zoledronic Acid for Hormone-Naïve Prostate Cancer: Long-Term Survival Results From an Adaptive, Multiarm, Multistage, Platform, Randomized Controlled Trial
title_full_unstemmed Adding Celecoxib With or Without Zoledronic Acid for Hormone-Naïve Prostate Cancer: Long-Term Survival Results From an Adaptive, Multiarm, Multistage, Platform, Randomized Controlled Trial
title_sort Adding Celecoxib With or Without Zoledronic Acid for Hormone-Naïve Prostate Cancer: Long-Term Survival Results From an Adaptive, Multiarm, Multistage, Platform, Randomized Controlled Trial
author_id_str_mv fdab5e9e2fe06c93d3ffa19c816bdcf6
author_id_fullname_str_mv fdab5e9e2fe06c93d3ffa19c816bdcf6_***_John Wagstaff
author John Wagstaff
author2 Malcolm D. Mason
Noel W. Clarke
Nicholas D. James
David P. Dearnaley
Melissa R. Spears
Alastair W.S. Ritchie
Gerhardt Attard
William Cross
Rob J. Jones
Christopher C. Parker
J. Martin Russell
George N. Thalmann
Francesca Schiavone
Estelle Cassoly
David Matheson
Robin Millman
Cyrill A. Rentsch
Jim Barber
Clare Gilson
Azman Ibrahim
John Logue
Anna Lydon
Ashok D. Nikapota
Joe M. O’Sullivan
Emilio Porfiri
Andrew Protheroe
Narayanan Nair Srihari
David Tsang
John Wagstaff
Jan Wallace
Catherine Walmsley
Mahesh K.B. Parmar
Matthew R. Sydes
format Journal article
container_title Journal of Clinical Oncology
container_volume 35
container_issue 14
container_start_page 1530
publishDate 2017
institution Swansea University
issn 0732-183X
1527-7755
doi_str_mv 10.1200/JCO.2016.69.0677
college_str Faculty of Medicine, Health and Life Sciences
hierarchytype
hierarchy_top_id facultyofmedicinehealthandlifesciences
hierarchy_top_title Faculty of Medicine, Health and Life Sciences
hierarchy_parent_id facultyofmedicinehealthandlifesciences
hierarchy_parent_title Faculty of Medicine, Health and Life Sciences
department_str Swansea University Medical School - Medicine{{{_:::_}}}Faculty of Medicine, Health and Life Sciences{{{_:::_}}}Swansea University Medical School - Medicine
document_store_str 1
active_str 0
description In this multiform, multistage trial 1245 men with high risk locally advanced or metastatic prostate cancer were treated with standard of care hormone therapy (SOCHT) and randomised (2:1:1) to receive SOCHT alone, SOCHT plus celecoxib (cel) or SOCHT plus cele plus zoledronic acid (ZA). Prostate (+/- pelvic) radiotherapy was encouraged for men with localised disease. In the SOCHT arm median survival was 66 months. The hazard ratio for death in the SOCHT + cel arm was 0.98 (95% CI 0.80 to 1.20, median survival 70 months, p=0.847). The hazard ratio for death in the SOCHT + cel + ZA was 0.86 (95% CI 0.70 to 1.05, median survival 76 months, p=0.13). these data show no overall evidence of improved survival with cel.
published_date 2017-05-10T19:06:54Z
_version_ 1821342972600385536
score 11.04748

Similar Items